Printer Friendly

Isaacs Named Chief Medical Officer of Entasis Therapeutics.


- US-based antibacterial drug developer Entasis Therapeutics has appointed Robin David Isaacs, M.D., as chief medical officer, the company said on Wednesday.

Isaacs has experience as a pharmaceutical executive in the development and launch of vaccine and infectious disease products.

He has held positions of increasing responsibility at Merck and Co., Inc. Most recently, he held the title of vice president and therapeutic area head, vaccine clinical research.

During his 18 years at Merck, Isaacs was involved with the worldwide development, regulatory submission, and approval of many anti-infective, antiviral, and vaccine products.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections.

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Date:Jul 15, 2015
Previous Article:Geneuity to Expand Pharmaceutical Services Using Thermo Fisher's Oncomine Assay.
Next Article:Diagnostics Company Theranos Teams with AmeriHealth Caritas.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters